Journal ArticleUnknown
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management
Authors
Author Affiliations
Union Hospital, Huazhong University of Science and Technology, Hubei University, State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing, ...
Published InEuropean Journal of Nuclear Medicine and Molecular Imaging
Year2022
Citations28
Abstract
Purpose Gallium-68-labeled fibroblast activation protein inhibitor ( 68 Ga-FAPI) is an emerging promising tumor tracer. This study aims to evaluate the diagnostic efficiency of 68 Ga-FAPI PET in gastrointestinal cancer, and to determine its potential impact on clinical management. Methods Patients with malignancies were prospectively enrolled in a clinical trial to evaluate the diagnostic value of 68 Ga-FAPI PET. One hundred twenty patients with gastrointestinal malignancies (121 68 Ga-FAPI PET scans) between June 2020 and May 2021 were retrospectively analyzed. Initial staging of untreated patients and restaging of treated patients were evaluated. The treatment scheme promoted by imaging was determined according to NCCN guidelines. Final diagnosis and treatment reference standards were determined by a dedicated multidisciplinary team. The diagnostic performance…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.